Clinical Research Directory

Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Willing to undergo an intraoperative biopsy/or standard of care tissue collection during surgery, following completion of treatment with MA +/- PTE * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Histologically confirmed EC or complex atypical hyperplasia of the endometrium * Candidate for a total hysterectomy with or without bilateral salpingo-oophorectomy * About to initiate preoperative window period, with planned hysterectomy scheduled * Platelets \>= 100,000/mm\^3 * NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement * Total bilirubin =\< 1.5 X upper limit of normal (ULN) * Aspartate aminotransferase (AST) =\< 1.5 x ULN * Alanine aminotransferase (ALT) =\< 1.5 x ULN * Creatinine clearance of \>= 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula * Women of childbearing potential: negative urine or serum pregnancy test in premenopausal women. Postmenopausal women do not need to undergo a pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required Exclusion Criteria: * Pterostilbene supplements within 30 days prior to day 1 of protocol therapy * Any of the following phytochemical-based supplements within 30 days prior to day 1 of protocol therapy: resveratrol, genistein, and quercetin * Chemotherapy for EC * Allergic reaction/hypersensitivity to similar agents, excipients * Unstable cardiac disease as defined by one of the following: * Cardiac events such as myocardial infarction (MI) within the past 6 months * NYHA (New York Heart Association) heart failure class III-IV * Uncontrolled atrial fibrillation or hypertensive emergency/urgency (defined as systolic blood pressure \>= 180 mmHg and/or diastolic blood pressure \>= 120 mmHg) * Active or history of recent thromboembolism or stroke, within the past 6 months * Cushing's syndrome * Acute infection requiring systemic (intravenous) treatment * Known history of human immunodeficiency virus (HIV) infection * Known active hepatitis B or C infection * Inability to swallow tablets/capsules * Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues, etc * Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)